GORDON A. EWY, M.D.; RUFINO C. PABICO, M.D.; JOHN F. MAHER, M.D.; DANIEL H. MINTZ, M.D.
The oral hypoglycemic agent phenformin (N1-β-phenethylbiguanide hydrochloride (DBI⌖*)) was greeted with hopeful anticipation when Ungar, Freedman, and Shapiro (1) demonstrated its mode of action to be different from the endogenous insulin-stimulating effect of sulfonylureas. Many investigators have reported on the therapeutic efficacy of phenformin, not only in ketoacidosis-resistant diabetes (2, 3), but also as an adjuvant to insulin therapy in juvenile diabetes (4) and in the treatment of insulin resistance (5, 6).
It had been observed that patients prone to ketoacidosis could develop ketosis without associated hyperglycemia when treated with prenformin (3, 4, 7). Concern was occasioned by the reports
EWY GA, PABICO RC, MAHER JF, et al. Lactate Acidosis Associated with Phenformin Therapy and Localized Tissue Hypoxia: Report of a Case Treated by Hemodialysis. Ann Intern Med. 1963;59:878–883. doi: https://doi.org/10.7326/0003-4819-59-6-878
Download citation file:
Published: Ann Intern Med. 1963;59(6):878-883.
Endocrine and Metabolism, Nephrology, Renal Replacement Therapy.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use